May 22, 2024 | HighField Bio Press Release

American Society of Clinical Oncology
2024 Annual Meeting
May 31 - June 4, Chicago

HighField Bio Founder and CEO, Yuhong Xu will present a poster on June 1st.

The poster, titledThe design, preclinical study and Phase 1 dose escalation of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment,” will be presented Saturday, June 1, 2024 (9am -12pm).